三级淋巴结构在肿瘤免疫微环境调节和抗肿瘤治疗中的作用

摘要/Abstract

摘要：

三级淋巴结构（TLS）是肿瘤免疫细胞浸润的重要通道，肿瘤TLS的存在与患者预后相关，也与多种抗肿瘤治疗的疗效相关。探讨TLS的功能、免疫调控机制以及作为肿瘤预后生物标志物对综合抗肿瘤治疗的潜在价值，可为后续相关研究提供新的思路。

曹梦清, 徐志勇, 施毓婷, 王凯. 三级淋巴结构在肿瘤免疫微环境调节和抗肿瘤治疗中的作用[J]. 国际肿瘤学杂志, 2023, 50(3): 169-173.

Cao Mengqing, Xu Zhiyong, Shi Yuting, Wang Kai. Role of tertiary lymphoid structures in tumor immune microenvironment regulation and anti-tumor therapy[J]. Journal of International Oncology, 2023, 50(3): 169-173.

参考文献39

[1]	Pfannstiel C, Strissel PL, Chiappinelli KB, et al. The tumor immune microenvironment drives a prognostic relevance that correlates with bladder cancer subtypes[J]. Cancer Immunol Res, 2019, 7(6): 923-938. DOI: 10.1158/2326-6066.CIR-18-0758. doi:10.1158/2326-6066.CIR-18-0758pmid:30988029
[2]	Vaghjiani RG, Skitzki JJ. Tertiary lymphoid structures as mediators of immunotherapy response[J]. Cancers (Basel), 2022, 14(15): 3748. DOI: 10.3390/cancers14153748. doi:10.3390/cancers14153748
[3]	Zhang Y, Wang F, Sun HR, et al. Apatinib combined with PD-L1 blockade synergistically enhances antitumor immune responses and promotes HEV formation in gastric cancer[J]. J Cancer Res Clin Oncol, 2021, 147(8): 2209-2222. DOI: 10.1007/s00432-021-03633-3. doi:10.1007/s00432-021-03633-3pmid:33891173
[4]	Cabrita R, Lauss M, Sanna A, et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma[J]. Nature, 2020, 577(7791): 561-565. DOI: 10.1038/s41586-019-1914-8. doi:10.1038/s41586-019-1914-8
[5]	Jia W, Zhang T, Yao Q, et al. Tertiary lymphatic structures in primary hepatic carcinoma: controversy cannot overshadow hope[J]. Front Immunol, 2022, 13: 870458. DOI: 10.3389/fimmu.2022.870458. doi:10.3389/fimmu.2022.870458
[6]	Dieudé M, Kaci I, Hébert MJ. The impact of programmed cell death on the formation of tertiary lymphoid structures[J]. Front Immunol, 2021, 12: 696311. DOI: 10.3389/fimmu.2021.696311. doi:10.3389/fimmu.2021.696311
[7]	Schumacher TN, Thommen DS. Tertiary lymphoid structures in cancer[J]. Science, 2022, 375(6576): eabf9419. DOI: 10.1126/science.abf9419. doi:10.1126/science.abf9419
[8]	Koning JJ, Mebius RE. Stromal cells and immune cells involved in formation of lymph nodes and their niches[J]. Curr Opin Immunol, 2020, 64: 20-25. DOI: 10.1016/j.coi.2020.03.003. doi:S0952-7915(20)30026-1pmid:32325389
[9]	KleinJan A, van Nimwegen M, Leman K, et al. Involvement of dendritic cells and Th17 cells in induced tertiary lymphoid structures in a chronic beryllium disease mouse model[J]. Mediators Inflamm, 2021, 2021: 8845966. DOI: 10.1155/2021/8845966. doi:10.1155/2021/8845966
[10]	Coleby R, Lucchesi D, Pontarini E, et al. Stepwise changes in the murine salivary gland immune response during virally-induced ectopic lymphoid structure formation[J]. Clin Exp Rheumatol, 2021, 39 Suppl 133(6):39-48. DOI: 10.55563/clinexprheumatol/gb7pfc. doi:10.55563/clinexprheumatol/gb7pfcpmid:34596023
[11]	Hill DG, Ward A, Nicholson LB, et al. Emerging roles for IL-6 family cytokines as positive and negative regulators of ectopic lymphoid structures[J]. Cytokine, 2021, 146: 155650. DOI: 10.1016/j.cyto.2021.155650. doi:10.1016/j.cyto.2021.155650
[12]	N J, J T, Sl N, et al. Tertiary lymphoid structures and B lymphocytes in cancer prognosis and response to immunotherapies[J]. Oncoimmunology, 2021, 10(1): 1900508. DOI: 10.1080/2162402X.2021.1900508. doi:10.1080/2162402X.2021.1900508
[13]	Simmons S, Sasaki N, Umemoto E, et al. High-endothelial cell-derived S1P regulates dendritic cell localization and vascular integrity in the lymph node[J]. Elife, 2019, 8: e41239. DOI: 10.7554/eLife.41239. doi:10.7554/eLife.41239
[14]	Tooley KA, Escobar G, Anderson AC. Spatial determinants of CD8⁺T cell differentiation in cancer[J]. Trends Cancer, 2022, 8(8): 642-654. DOI: 10.1016/j.trecan.2022.04.003. doi:10.1016/j.trecan.2022.04.003
[15]	Asrir A, Tardiveau C, Coudert J, et al. Tumor-associated high endothelial venules mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 combination immunotherapy[J]. Cancer Cell, 2022, 40(3): 318-334. e9. DOI: 10.1016/j.ccell.2022.01.002. doi:10.1016/j.ccell.2022.01.002pmid:35120598
[16]	Dangaj D, Bruand M, Grimm AJ, et al. Cooperation between constitutive and inducible chemokines enables T cell engraftment and immune attack in solid tumors[J]. Cancer Cell, 2019, 35(6): 885-900. e10. DOI: 10.1016/j.ccell.2019.05.004. doi:S1535-6108(19)30242-9pmid:31185212
[17]	Woods AN, Wilson AL, Srivinisan N, et al. Differential expression of homing receptor ligands on tumor-associated vasculature that control CD8 effector t-cell entry[J]. Cancer Immunol Res, 2017, 5(12): 1062-1073. DOI: 10.1158/2326-6066.CIR-17-0190. doi:10.1158/2326-6066.CIR-17-0190pmid:29097419
[18]	Patil NS, Nabet BY, Müller S, et al. Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer[J]. Cancer Cell, 2022, 40(3): 289-300. e4. DOI: 10.1016/j.ccell.2022.02.002. doi:10.1016/j.ccell.2022.02.002pmid:35216676
[19]	Siddiqui I, Schaeuble K, Chennupati V, et al. Intratumoral Tcf1⁺PD-1⁺CD8⁺T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy[J]. Immunity, 2019, 50(1): 195-211. e10. DOI: 10.1016/j.immuni.2018.12.021. doi:S1074-7613(18)30569-7pmid:30635237
[20]	Kurtulus S, Madi A, Escobar G, et al. Checkpoint blockade immunotherapy induces dynamic changes in PD-1^-CD8⁺tumor-infiltrating T cells[J]. Immunity, 2019, 50(1): 181-194. e6. DOI: 10.1016/j.immuni.2018.11.014. doi:S1074-7613(18)30522-3pmid:30635236
[21]	Di Pilato M, Kfuri-Rubens R, Pruessmann JN, et al. CXCR6 positions cytotoxic T cells to receive critical survival signals in the tumor microenvironment[J]. Cell, 2021, 184(17): 4512-4530. e22. DOI: 10.1016/j.cell.2021.07.015. doi:10.1016/j.cell.2021.07.015pmid:34343496
[22]	Mustapha R, Ng K, Monypenny J, et al. Insights into unveiling a potential role of tertiary lymphoid structures in metastasis[J]. Front Mol Biosci, 2021, 8: 661516. DOI: 10.3389/fmolb.2021.661516. doi:10.3389/fmolb.2021.661516
[23]	Kuwabara S, Tsuchikawa T, Nakamura T, et al. Prognostic rele-vance of tertiary lymphoid organs following neoadjuvant chemoradiotherapy in pancreatic ductal adenocarcinoma[J]. Cancer Sci, 2019, 110(6): 1853-1862. DOI: 10.1111/cas.14023. doi:10.1111/cas.14023
[24]	Boivin G, Kalambaden P, Faget J, et al. Cellular composition and contribution of tertiary lymphoid structures to tumor immune infiltration and modulation by radiation therapy[J]. Front Oncol, 2018, 8: 256. DOI: 10.3389/fonc.2018.00256. doi:10.3389/fonc.2018.00256pmid:30038899
[25]	Lin Q, Tao P, Wang J, et al. Tumor-associated tertiary lymphoid structure predicts postoperative outcomes in patients with primary gastrointestinal stromal tumors[J]. Oncoimmunology, 2020, 9(1): 1747339. DOI: 10.1080/2162402X.2020.1747339. doi:10.1080/2162402X.2020.1747339
[26]	Inoue H, Horii R, Ito Y, et al. Tumor-infiltrating lymphocytes affect the efficacy of trastuzumab-based treatment in human epidermal growth factor receptor 2-positive breast cancer[J]. Breast Cancer, 2018, 25(3): 268-274. DOI: 10.1007/s12282-017-0822-8. doi:10.1007/s12282-017-0822-8pmid:29185202
[27]	Qi Z, Xu Z, Zhang L, et al. Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by intermittent anti-PI3Kα/β/δ treatment[J]. Nat Commun, 2022, 13(1): 182. DOI: 10.1038/s41467-021-27833-0. doi:10.1038/s41467-021-27833-0pmid:35013322
[28]	van Dijk N, Gil-Jimenez A, Silina K, et al. Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial[J]. Nat Med, 2020, 26(12): 1839-1844. DOI: 10.1038/s41591-020-1085-z. doi:10.1038/s41591-020-1085-zpmid:33046870
[29]	Vanhersecke L, Brunet M, Guégan JP, et al. Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression[J]. Nat Cancer, 2021, 2(8): 794-802. DOI: 10.1038/s43018-021-00232-6. doi:10.1038/s43018-021-00232-6
[30]	Gray KD, McCloskey JE, Vedvyas Y, et al. PD1 blockade enhances ICAM1-directed CAR T therapeutic efficacy in advanced thyroid cancer[J]. Clin Cancer Res, 2020, 26(22): 6003-6016. DOI: 10.1158/1078-0432.CCR-20-1523. doi:10.1158/1078-0432.CCR-20-1523
[31]	Zhang W, Huang Q, Xiao W, et al. Advances in anti-tumor treatments targeting the CD47/SIRPα axis[J]. Front Immunol, 2020, 11: 18. DOI: 10.3389/fimmu.2020.00018. doi:10.3389/fimmu.2020.00018pmid:32082311
[32]	Li H, Wang J, Liu H, et al. Existence of intratumoral tertiary lymphoid structures is associated with immune cells infiltration and predicts better prognosis in early-stage hepatocellular carcinoma[J]. Aging (Albany NY), 2020, 12(4): 3451-3472. DOI: 10.18632/aging.102821. doi:10.18632/aging.102821
[33]	Ding GY, Ma JQ, Yun JP, et al. Distribution and density of tertiary lymphoid structures predict clinical outcome in intrahepatic cholangiocarcinoma[J]. J Hepatol, 2022, 76(3): 608-618. DOI: 10.1016/j.jhep.2021.10.030. doi:10.1016/j.jhep.2021.10.030
[34]	Li H, Liu H, Fu H, et al. Peritumoral tertiary lymphoid structures correlate with protective immunity and improved prognosis in patients with hepatocellular carcinoma[J]. Front Immunol, 2021, 12: 648812. DOI: 10.3389/fimmu.2021.648812. doi:10.3389/fimmu.2021.648812
[35]	Park HS, Kim YM, Kim S, et al. High endothelial venule is a surrogate biomarker for T-cell inflamed tumor microenvironment and prognosis in gastric cancer[J]. J Immunother Cancer, 2021, 9(10): e003353. DOI: 10.1136/jitc-2021-003353. doi:10.1136/jitc-2021-003353
[36]	Zhan Z, Shi-Jin L, Yi-Ran Z, et al. High endothelial venules proportion in tertiary lymphoid structure is a prognostic marker and correlated with anti-tumor immune microenvironment in colorectal cancer[J]. Ann Med, 2023, 55(1): 114-126. DOI: 10.1080/07853890.2022.2153911. doi:10.1080/07853890.2022.2153911pmid:36503344
[37]	J Gunderson A, Rajamanickam V, Bui C, et al. Germinal center reactions in tertiary lymphoid structures associate with neoantigen burden, humoral immunity and long-term survivorship in pancreatic cancer[J]. Oncoimmunology, 2021, 10(1): 1900635. DOI: 10.1080/2162402X.2021.1900635. doi:10.1080/2162402X.2021.1900635
[38]	Ruffin AT, Cillo AR, Tabib T, et al. B cell signatures and tertiary lymphoid structures contribute to outcome in head and neck squamous cell carcinoma[J]. Nat Commun, 2021, 12(1): 3349. DOI: 10.1038/s41467-021-23355-x. doi:10.1038/s41467-021-23355-xpmid:34099645
[39]	Meylan M, Petitprez F, Lacroix L, et al. Early hepatic lesions display immature tertiary lymphoid structures and show elevated expression of immune inhibitory and immunosuppressive molecules[J]. Clin Cancer Res, 2020, 26(16): 4381-4389. DOI: 10.1158/1078-0432.CCR-19-2929. doi:10.1158/1078-0432.CCR-19-2929pmid:32269054

三级淋巴结构在肿瘤免疫微环境调节和抗肿瘤治疗中的作用

Role of tertiary lymphoid structures in tumor immune microenvironment regulation and anti-tumor therapy

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献39

相关文章15

编辑推荐

Metrics

本文评价

[1]	钱晓涛, 石子宜, 胡格, 吴晓维.Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[2]	傅旖, 马辰莺, 张露, 周菊英.生境分析在恶性肿瘤影像组学中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(5): 292-297.
[3]	王昆, 周中新, 臧其威.血清TGF-β1、VEGF水平对非小细胞肺癌患者单孔胸腔镜根治术后复发的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 198-203.
[4]	杨智, 陆以乔, 顾花艳, 丁佳玲, 郭贵龙.肿瘤微环境介导乳腺癌靶向治疗耐药的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 235-238.
[5]	严爱婷, 王翠竹, 刘春桂, 鲁小敏.卡瑞利珠单抗与信迪利单抗治疗晚期非小细胞肺癌的临床疗效及安全性分析[J]. 国际肿瘤学杂志, 2024, 51(3): 137-142.
[6]	姜溪, 武永存, 梁艳, 楚丽, 段颖欣, 王力军, 霍俊杰.派安普利单抗联合化疗对晚期非小细胞肺癌患者血管生成及循环内皮细胞的影响[J]. 国际肿瘤学杂志, 2024, 51(2): 89-94.
[7]	高新雨, 李振江, 孙洪福, 韩丹, 赵倩, 刘成新, 黄伟.基于MR加速器的MR引导放疗在食管癌患者中的临床应用[J]. 国际肿瘤学杂志, 2024, 51(1): 37-42.
[8]	刘筱迪, 苏剑飞, 张静娴, 卫雪芹, 贾英杰.髓源性抑制细胞在肿瘤血管生成中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(1): 50-54.
[9]	顾花艳, 朱腾, 郭贵龙.乳房微生物群与乳腺癌：现状与未来[J]. 国际肿瘤学杂志, 2024, 51(1): 55-58.
[10]	许萌, 姜伟, 朱海涛, 曹雄锋.癌相关成纤维细胞在肿瘤放疗抵抗中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 227-230.
[11]	丁浩, 应劲涛, 付茂勇.CAR-T在食管鳞状细胞癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 231-235.
[12]	周婷, 徐少华, 梅林.贝伐珠单抗联合卡培他滨治疗晚期乳腺癌的有效性及安全性[J]. 国际肿瘤学杂志, 2023, 50(3): 144-149.
[13]	徐良富, 李袁飞.MSS型结直肠癌肿瘤微环境及免疫联合治疗研究进展[J]. 国际肿瘤学杂志, 2023, 50(3): 186-190.
[14]	朱易, 陈健.硫化氢在肿瘤发生发展中的作用机制及其供体抗肿瘤作用[J]. 国际肿瘤学杂志, 2023, 50(12): 729-733.
[15]	王冰, 王爱馥, 刘雯舒, 范娇娇, 田伟成, 王玮莉, 刘博宇.重组人血小板生成素治疗肿瘤放疗所致血小板减少症的疗效及安全性[J]. 国际肿瘤学杂志, 2023, 50(11): 661-667.